R1 Therapeutics raises $77.5m to progress AP306 for hyperphosphatemia

AP306 is under development as a monotherapy for hyperphosphatemia in CKD patients. Credit: sweet_tomato / Shutterstock.com.



  • R1 Therapeutics AP306